Nicholas Haft
Fondatore presso Delix Therapeutics, Inc.
Profilo
Nicholas Haft is the founder of Delix Therapeutics, Inc. He is currently the Director at Arcos Ventures SPV LLC.
Previously, he served as the Independent Director at Finch Therapeutics Group, Inc. from 2020 to 2023.
He completed his undergraduate degree at The Wharton School of the University of Pennsylvania.
Posizioni attive di Nicholas Haft
| Società | Posizione | Inizio |
|---|---|---|
Delix Therapeutics, Inc.
 Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | Fondatore | - |
| Arcos Ventures SPV LLC | Amministratore Delegato | 01/04/2015 |
Precedenti posizioni note di Nicholas Haft
| Società | Posizione | Fine |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Direttore/Membro del Consiglio | 23/06/2023 |
Formazione di Nicholas Haft
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Aziende private | 2 |
|---|---|
Delix Therapeutics, Inc.
Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | Health Technology |
| Arcos Ventures SPV LLC |
- Borsa valori
- Insiders
- Nicholas Haft